AVIRAtea Pharmaceuticals, Inc.
$5.15+73% 1Y
$5.15
$2.9652 weeks$6.15
AVIR in its own filings
Nothing in AVIR's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
83
Events found in the filings · across 313 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 12, 2026
Most recent filing · Form 10-Q
- Record starts
- Jul 16, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 11, 2026
- SEC comment-letter activity7 occurrences
- 2024-11-15
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 12, 2026Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Mar 5, 2026Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and.Earnings release · press release
- Jan 8, 2026Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare.Earnings release · press release
- Nov 12, 2025Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…